Journal
VASCULAR HEALTH AND RISK MANAGEMENT
Volume 13, Issue -, Pages 293-303Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/VHRM.S108874
Keywords
BCR-ABL; tyrosine kinase inhibitor; peripheral arterial disease; cardiovascular disease; adverse event
Categories
Funding
- Friends for Life Fund, Princess Margaret Hospital Foundation
Ask authors/readers for more resources
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML). Despite their significant impact on the management of CML, there is growing evidence that TKIs may cause cardiovascular and/or metabolic complications. In this review, we present the current evidence regarding the cardiovascular safety profiles of BCR-ABL TKIs. Methodological challenges of studies that reported the cardiovascular safety of TKIs are discussed. We also propose management strategies for cardiovascular surveillance and risk factor modification during treatment with these agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available